Drugs Flashcards
1
Q
Accrufer
ferric maltol
A
purpose: Treatment of iron deficiency anemia in adults unresponsive or intolerant to other oral iron preparations
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
2
Q
Adheroza
trastuzumab
A
purpose: Biosimilar to Herceptin
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
3
Q
Apretude
cabotegravir
A
purpose: Injectable antiretroviral (with optional oral lead-in) for HIV pre-exposure prophylaxis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
4
Q
Armlupeg
pegfilgrastim
A
purpose: Biosimilar to Neulasta
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
5
Q
Ayvakyt
avapritinib
A
purpose: Tyrosine kinase inhibitor for advanced systemic mastocytosis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
6
Q
Awiqli
insulin icodec
A
purpose: Long-acting, once-weekly insulin for adults with diabetes
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
7
Q
Cabtreo
clindamycin phosphate / adapalene / benzoyl peroxide
A
purpose: Gel for treatment of acne in patients ≥ 12 years of age
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
8
Q
Capvaxive
pneumococcal 21-valent conjugate vaccine
A
purpose: Vaccine for prevention of invasive pneumococcal disease in adults
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
9
Q
Casgevy
exagamglogene autotemcel
A
purpose: Gene-edited therapy for sickle cell disease with recurrent vaso-occlusive crises, and transfusion-dependent β-thalassemia
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
10
Q
Clorotekal
chloroprocaine hydrochloride B.
A
purpose: spinal anesthetic for surgical procedures in adults
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
11
Q
Combogesic IV
acetaminophen / ibuprofen
A
purpose: Analgesic for short-term management of pain or as an adjunct to opioid analgesics
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
12
Q
Comirnaty
COVID-19 mRNA vaccine, Omicron KP.2 variant
A
purpose: Vaccine for active immunization against COVID-19
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
13
Q
Ebglyss
lebrikizumab
A
purpose: Interleukin inhibitor monoclonal antibody for moderate-to-severe atopic dermatitis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
14
Q
Eylea HD
aflibercept
A
purpose: New higher-strength (8 mg/0.07 mL) solution (compared to Eylea)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
15
Q
Ferinject
ferric carboxymaltose
A
purpose: Treatment of iron deficiency anemia
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
16
Q
Fruzaqla
fruquintinib
A
purpose: Tyrosine kinase inhibitor for treatment of metastatic colorectal cancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
17
Q
Fruzaqla
fruquintinib
A
purpose: Tyrosine kinase inhibitor for treatment of metastatic colorectal cancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
18
Q
Imdelltra
tarlatamab
A
purpose: T-cell engager for extensive stage small cell lung cancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
19
Q
Ixchiq
chikungunya vaccine
A
purpose: Live, attenuated vaccine for prevention of disease caused by chikungunya virus in adults
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
20
Q
Jubbonti
denosumab
A
purpose: Biosimilar to Prolia
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
21
Q
Miebo
perfluorohexyloctane
A
purpose: Solution for treatment of dry eye disease
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
22
Q
Mounjaro KwikPen
tirzepatide injection
A
purpose: New multidose prefilled pen in various strengths
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
23
Q
Myalepta
metreleptin
A
purpose: Recombinant human leptin analog for treating complications of leptin deficiency in lipodystrophy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
24
Q
Niopeg
pegfilgrastim
A
purpose: Biosimilar to Neulasta
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
25
Nordimet
methotrexate
purpose: Single-use prefilled pens in various strengths for rheumatoid arthritis and psoriasis/psoriatic arthritis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
26
Nuvaxovid
COVID-19 vaccine, recombinant protein, adjuvanted, Omicron JN.1 variant
purpose: Vaccine for active immunization against COVID-19
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
27
Olumiant
baricitinib
purpose: New 4 mg tablet for treatment of adults with severe alopecia areata
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
28
Okedi
risperidone
purpose: Extended-release injectable suspension with two-syringe mixing system, given every 4 weeks
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
29
Opzelura
ruxolitinib
purpose: JAK inhibitor cream for nonsegmental vitiligo, and mild to moderate atopic dermatitis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
30
Plenvu
polyethylene glycol 3350 / sodium ascorbate / sodium sulfate anhydrous / ascorbic acid / sodium chloride / potassium chloride
purpose: Powder for oral solution; an osmotic laxative colonoscopy preparation solution for adults
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
31
Pyzchiva / Pyzchiva I.V
ustekinumab
purpose: Biosimilar to Stelara / Stelara I.V.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
32
Rybelsus
semaglutide, optimized formulation
purpose: New tablet formulation with an absorption enhancer (1.5 mg, 4 mg and 9 mg strengths)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
33
Spikevax
COVID-19 mRNA vaccine, Omicron KP.2 variant
purpose: Active immunization against COVID-19
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
34
Steqeyma / Steqeyma I.V
ustekinumab
purpose: Biosimilar to Stelara / Stelara I.V.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
35
Talvey
talquetamab
purpose: Antineoplastic monoclonal antibody for relapsed or refractory multiple myeloma
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
36
Tecentriq SC
atezolizumab
purpose: New SC format for patients who wish to transition from an IV to SC dosage form
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
37
Tibsovo
ivosidenib
purpose: Mutant IDH1 enzyme inhibitor for acute myeloid leukemia or metastatic cholangiocarcinoma
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
38
Truqap
capivasertib
purpose: AKT (serine/threonine kinase) inhibitor for HR+, HER2-negative locally advanced or metastatic breast cancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
39
Tyenne
tocilizumab
purpose: A biosimilar to Actemra
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
40
Velsipity
etrasimod
purpose: Sphingosine 1-phosphate receptor modulator for adults with moderately to severely active ulcerative colitis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
41
Voranigo
vorasidenib
purpose: IDH1 / IDH2 enzyme inhibitor for Grade 2a astrocytoma or oligodendroglioma
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
42
Voydeya
danicopan
purpose: Complement inhibitor; add-on therapy in paroxysmal nocturnal hemoglobinuria
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
43
Wainua
eplontersen
purpose: Antisense oligonucleotide for hereditary transthyretin-mediated amyloidosis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
44
Winrevair
sotatercept
purpose: Activin signalling inhibitor for treatment of pulmonary arterial hypertension
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
45
Wyost
denosumab
purpose: Biosimilar to Xgeva
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
46
Xenpozyme
olipudase alfa
purpose: Enzyme replacement therapy for long-term treatment of non-CNS manifestations of acid sphingomyelinase deficiency
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
47
Zilbrysq
zilucoplan
purpose: Complement C5 inhibitor for generalized myasthenia gravis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
48
Ayvakyt
avapritinib
purpose: for advanced systemic mastocytosis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
49
Casgevy
exagamglogene autotemcel
purpose: a gene-edited therapy for sickle cell disease and transfusion-dependent β-thalassemia
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
50
Opzelura
ruxolitinib
purpose: a topical JAK inhibitor cream for vitiligo and mild/moderate atopic dermatitis
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
51
Rybelsus
semaglutide
purpose: optimized formulation with an absorption enhancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
52
Tyenne
tocilizumab
purpose: a biosimilar to Actemra
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
53
Uplizna
Inebilizumab
purpose: Neuromyelitis optica spectrum disorder
MOA: Immunosuppressants
sig:
monitoring ade:
monitoring efficacy:
interactions:
54
Velsipity
Etrasimod
purpose: Ulcerative colitis
MOA: L04 Immunosuppressants
sig:
monitoring ade:
monitoring efficacy:
interactions:
55
Sibboran.
Landiolol hydrochloride
purpose: short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial fibrillation and atrial flutter in perioperative, postoperative, or other acute circumstances.
MOA: Beta blocking agents
sig:
monitoring ade:
monitoring efficacy:
interactions:
56
Xenpozyme
Olipudase alfa
purpose: Acid sphingomyelinase deficiency (historically known as Niemann-Pick disease)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
57
Ferinject.
ferric carboxymaltose
purpose: the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older when oral iron preparations are not tolerated or are ineffective.
the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
58
Beqvez.
Fidanacogene elaparvovec
purpose: moderately severe to severe hemophilia B (congenital Factor IX [FIX] deficiency)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
59
Arexvy.
Respiratory syncytial virus prefusion F protein (RSVPreF3)
purpose: prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
60
Comirnaty Omicron XBB.1.5.
Raxtozinameran
purpose: active immunization against coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 6 months of age and older.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
61
Livmarli.
Maralixibat (supplied as maralixibat chloride)
purpose: cholestatic pruritus in patients with Alagille syndrome (ALGS)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
62
Ondexxya
Andexanet alfa
purpose: rapid reversal of anticoagulation due to life‑threatening or uncontrolled bleeding related to rivaroxaban or apixaban
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
63
Sogroya
Somapacitan
purpose: the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency).
the replacement of endogenous growth hormone in adults with growth hormone deficiency.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
64
Spikevax XBB.1.5
Andusomeran
purpose: active immunization against coronavirus disease 2019 (COVID‑19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) virus in individuals 6 months of age and older
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
65
Imcivree
Setmelanotide
purpose: Bardet-Biedl syndrome (BBS), or
Genetically confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
66
Omvoh
Mirikizumab
purpose: Ulcerative colitis is a chronic inflammatory disease of the rectum and colon
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
67
Prehevbrio.
Hepatitis B Surface Antigen
purpose: active immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
68
Verquvo.
Vericiguat
purpose: symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
69
Xcopri.
Cenobamate
purpose: adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
70
Onakta.
Tirbanibulin
purpose: non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) on the face or scalp in adults.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
71
Quviviq.
Daridorexant
purpose: insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
72
Winlevi.
Clascoterone
purpose: acne vulgaris in patients 12 years of age and older
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
73
Beyfortus.
Nirsevimab
purpose:
Neonates and infants during their first RSV season.
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, which may include but is not limited to children with:
Chronic lung disease of prematurity (CLD)
Hemodynamically significant congenital heart disease (CHD)
Immunocompromised states
Down syndrome
Cystic fibrosis
Neuromuscular disease
Congenital airway anomalies.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
74
Locametz.
Kit for the preparation of gallium (68Ga) gozetotide solution for injection
purpose:
radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer:
with suspected metastasis who are candidates for initial definitive therapy.
with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
for identification of patients with progressive metastatic castration-resistant prostate cancer (mCRPC), for whom PSMA-targeted therapy is indicated.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
75
Spevigo.
Spesolimab
purpose: flares in adult patients with generalized pustular psoriasis (GPP)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
76
Qulipta.
Atogepant
purpose: prevention of episodic migraine (<15 migraine days per month) in adults
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
77
Alhemo.
Concizumab
purpose: adolescent and adult patients (12 years of age or older) with hemophilia B (congenital factor IX [FIX] deficiency) who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
78
Carvykti.
Ciltacabtagene autoleucel
purpose: adult patients with multiple myeloma, who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
79
Columvi.
Glofitamab
purpose: adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, diffuse large B-cell lymphoma arising from follicular lymphoma, or primary mediastinal B-cell lymphoma, who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR T-cell therapy or have previously received CAR T-cell therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
80
Vegzelma.
Bevacizumab
purpose: metastatic colorectal cancer; locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC); platinum-sensitive recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and malignant glioma (World Health Organization grade IV) - glioblastoma.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
81
Empaveli.
Pegcetacoplan
purpose: adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a complement component 5 (C5) inhibitor
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
82
Camzyos.
Mavacamten
purpose: symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association (NYHA) Class II-III in adult patients
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
83
Mounjaro.
Tirzepatide
purpose:
Once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus (T2DM).
As monotherapy when metformin is inappropriate due to contraindication or intolerance.
In combination with:
metformin, or
metformin and a sulfonylurea, or
metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or
basal insulin with or without metformin.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
84
Kengrexal.
Cangrelor
purpose: reducing the risk of thrombotic cardiovascular events (periprocedural myocardial infarction [MI], repeat coronary revascularization, and stent thrombosis [ST]) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not been treated with an oral P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
85
Sunlenca.
Lenacapavir
purpose: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment‑experienced adults with multidrug resistant (MDR) HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
86
Ubrelvy.
Ubrogepant
purpose: acute treatment of migraine with or without aura in adults.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
87
Elonox/Elonox HP.
Enoxaparin sodium
purpose: prevention of venous thromboembolic disease, treatment of deep vein thrombosis, treatment of unstable angina and non-Q-wave myocardial infarction concurrently with acetylsalicylic acid, and treatment of acute ST-segment elevation myocardial infarction.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
88
Ervebo.
Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live)
purpose: active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus (ZEBOV).
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
89
Sotyktu.
Deucravacitinib
purpose: adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
90
Sunlenca.
Lenacapavir
purpose: treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment‑experienced adults with multidrug resistant (MDR) HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
91
Illuccix.
Kit for the preparation of gallium (68Ga) gozetotide for intravenous injection
purpose: positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer:
with suspected metastasis who are suitable for initial definitive therapy.
with suspected recurrence with elevated serum prostate-specific antigen (PSA) level.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
92
Kerendia.
Finerenone
purpose: adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of:
end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate,
cardiovascular death, non‑fatal myocardial infarction and hospitalization for heart failure.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
93
Livtencity.
Maribavir
purpose: adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
94
Rymti.
Etanercept
purpose: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and plaque psoriasis in adult and pediatric patients.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
95
Cibinqo.
Abrocitinib
purpose: patients 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs (e.g., steroid or biologic), or for whom these treatments are not advisable
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
96
Myxredlin.
Insulin (human)
purpose: patients with diabetes mellitus who require insulin by intravenous administration for the control of hyperglycemia.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
97
Pluvicto.
Lutetium (177Lu) vipivotide tetraxetan
purpose: adult patients with prostate‑specific membrane antigen (PSMA)‑positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane‑based chemotherapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
98
Welireg.
Belzutifan
purpose: adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma (RCC), not requiring immediate surgery. Efficacy in patients with VHL disease-associated RCC was based on objective response rate and duration of response in a single-arm study
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
99
Tezspire.
Tezepelumab
purpose: adults and adolescents aged 12 years and older with severe asthma
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
100
Albrioza.
Sodium phenylbutyrate and ursodoxicoltaurine
purpose: patients with amyotrophic lateral sclerosis (ALS)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
101
Korsuva.
Difelikefalin (supplied as difelikefalin acetate)
purpose: moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis (HD)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
102
Koselugo.
Selumetinib (supplied as selumetinib sulfate)
purpose: pediatric patients aged 2 years and above with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
103
Orladeyo.
Berotralstat (supplied as berotralstat hydrochloride)
purpose: routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
104
Poteligeo.
Mogamulizumab
purpose: adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
105
Xpovio.
Selinexor
purpose: adult patients with multiple myeloma who have received at least one prior therapy.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
106
Bimzelx.
Bimekizumab
purpose: moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
107
Kimmtrak.
Tebentafusp
purpose: human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
108
Scemblix.
Asciminib (supplied as asciminib hydrochloride)
purpose: adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
109
Breyanzi.
Lisocabtagene maraleucel
purpose: adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including: diffuse large B-cell lymphoma (DLBCL) not otherwise specified; primary mediastinal large B-cell lymphoma (PMBCL); high grade B-cell lymphoma; and DLBCL arising from follicular lymphoma.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
110
Byooviz.
Ranibizumab
purpose: neovascular (wet) age-related macular degeneration;
visual impairment due to diabetic macular edema;
visual impairment due to macular edema secondary to retinal vein occlusion;
visual impairment due to choroidal neovascularization secondary to pathologic myopia;
visual impairment due to choroidal neovascularization secondary to ocular conditions other than age-related macular degeneration or pathologic myopia, including but not limited to angioid streaks, post- inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
111
Prevnar 20.
Pneumococcal 20-valent conjugate vaccine (diphtheria cross-reactive material 197 [CRM197] protein)
purpose: prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
112
Semglee.
Insulin glargine
purpose: for once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 (T1DM) or Type 2 (T2DM) diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.
in the treatment of pediatric patients (over 6 years old) with Type 1 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
113
Vabysmo.
Faricimab
purpose: neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME)
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
114
Tabrecta.
Capmatinib
purpose: adult patients with locally advanced unresectable or metastatic non‑small cell lung cancer (NSCLC) harbouring mesenchymal‑epithelial transition (MET) exon 14 (METex14) skipping alterations
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
115
Vraylar.
Cariprazine
purpose: Schizophrenia
Vraylar (cariprazine) is indicated for:
the treatment of schizophrenia in adults.
Bipolar I disorder
Bipolar Mania: acute management of manic or mixed episodes associated with bipolar I disorder in adults, and
Bipolar Depression: acute management of depressive episodes associated with bipolar I disorder in adults.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
116
Tavneos.
Avacopan
purpose: adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard background therapy including glucocorticoids
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
117
Palynziq.
Pegvaliase
purpose: reduction of blood phenylalanine concentrations in patients with phenylketonuria (PKU) aged 16 years and older who blood phenylalanine levels greater than 600 micromol/L
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
118
Rholistiq.
Belumosudil
purpose: adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
119
Rybrevant.
Amivantamab
purpose: adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
120
Evusheld.
Tixagevimab and Cilgavimab
purpose: pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg), who have not had a known recent exposure to an individual infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and:
who are immune compromised and unlikely to mount an adequate immune response to COVID-19 vaccination; or
for whom COVID-19 vaccination is not recommended.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
121
HyQvia.
Normal immunoglobulin (human) and recombinant human hyaluronidase
purpose: replacement therapy for primary humoral immunodeficiency and secondary humoral immunodeficiency in adult patients.
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
122
Ontruzant.
Trastuzumab
purpose: human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
123
Oxlumo.
Lumasiran
purpose: primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
124
Rholistiq.
Belumosudil
purpose: adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
125
Rybrevant.
Amivantamab
purpose: adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
126
Sohonos.
Palovarotene
purpose: reduction of the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia (myositis) ossificans progressiva
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
127
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
128
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
129
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
130
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
131
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
132
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
132
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
133
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
133
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
134
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
135
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
136
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
137
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
138
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
139
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
140
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
141
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
141
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
142
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
142
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
143
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
144
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
145
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
145
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
145
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
146
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
147
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
148
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
149
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
150
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
151
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
152
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
153
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
154
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
155
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
156
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
157
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
158
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
159
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
160
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
161
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
162
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
163
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
164
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
165
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
166
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
167
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
168
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
169
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
170
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
171
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
172
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
173
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
174
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
175
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
176
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
177
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
178
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
179
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
180
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
181
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
182
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
183
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
184
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
185
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
185
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
186
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
187
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
188
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
189
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
190
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
191
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
192
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
193
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
194
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
195
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
196
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
196
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
197
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
198
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
199
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
200
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
201
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
202
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
203
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
204
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
204
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
205
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
206
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
206
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
207
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
208
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
209
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
210
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
211
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
212
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
213
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
214
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
215
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
215
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
216
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
217
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
217
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
218
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
219
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
219
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
220
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
221
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
222
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
223
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
224
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
225
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
226
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
226
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
227
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
227
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
228
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
229
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
230
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
231
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
232
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
232
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
233
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
234
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
235
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
236
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
237
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
238
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
239
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
240
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
240
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
241
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
242
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
243
purpose:
MOA:
sig:
monitoring ade:
monitoring efficacy:
interactions:
